Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study.
M'Baloula J, Tougeron D, Boilève A, Jeanbert E, Guimbaud R, Ben Abdelghani M, Durand A, Turpin A, Quesada S, Blanc JF, Artru P, Toullec C, Trouilloud I, Pellat A, Touchefeu Y, Pinot J, Caroli-Bosc FX, Taïeb J, Doat S, Bouché O, Védie AL, de Mestier L, Muller M. M'Baloula J, et al. Among authors: toullec c. Eur J Cancer. 2024 Nov;212:115051. doi: 10.1016/j.ejca.2024.115051. Epub 2024 Oct 1. Eur J Cancer. 2024. PMID: 39366210 Free article.
Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study.
Adhoute X, Gonzalez A, Levi-Strauss T, Mineur L, Pénaranda G, Sellier F, Toullec C, Pietri O, Castellani P, Tran A, Perrier H, Bourliere M, Anty R. Adhoute X, et al. Among authors: toullec c. Eur J Gastroenterol Hepatol. 2024 Nov 1;36(11):1329-1339. doi: 10.1097/MEG.0000000000002830. Epub 2024 Jul 26. Eur J Gastroenterol Hepatol. 2024. PMID: 39083056
Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.
Botsen D, Chabaud S, Perrier H, Ammarguellat H, Jestin-Le-Tallec V, Olesinski J, Toullec C, Aparicio T, Ben Abdelghani M, Borg C, Bouche O, Coutzac C, Devaud H, Di Fiore F, Dubreuil O, Evesque L, Huguenin B, Muller M, Poureau PG, Oularue E, Tougeron D, Zaanan A, Ammari S, De Sousa Carvalho N, Decazes P, De La Fouchardiere C. Botsen D, et al. Among authors: toullec c. Dig Liver Dis. 2024 Aug;56(8):1281-1287. doi: 10.1016/j.dld.2024.04.032. Epub 2024 May 17. Dig Liver Dis. 2024. PMID: 38762353 Free article.
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study.
Varnier R, Toullec C, Philonenko S, Dupré A, Artru P, Hafliger E, Drouillard A, Torregrosa C, Pernot S, McLellan P, Lecomte T, Moulin V, Lécaille C, Touchefeu Y, Locher C, Taieb J, Coutzac C. Varnier R, et al. Among authors: toullec c. Dig Liver Dis. 2024 Sep;56(9):1605-1613. doi: 10.1016/j.dld.2024.02.009. Epub 2024 Feb 24. Dig Liver Dis. 2024. PMID: 38403514
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
Taïeb J, Bouche O, André T, Le Malicot K, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, Corbinais S, Perrier H, Buecher B, Di Fiore F, Gallois C, Emile JF, Lepage C, Elhajbi F, Tougeron D; SAMCO-PRODIGE 54 Investigators. Taïeb J, et al. Among authors: toullec c. JAMA Oncol. 2023 Oct 1;9(10):1356-1363. doi: 10.1001/jamaoncol.2023.2761. JAMA Oncol. 2023. PMID: 37535388 Free PMC article.
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.
Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, Prager GW, Pietrantonio F, Antista M, Ghelardi F, Basile D, Aprile G, Longarini R, Hautefeuille V, Tougeron D, Artru P, Mabro M, Drouillard A, Roth G, Ben Abdelghani M, Clement I, Toullec C, Mineur L, Guimbaud R, Taieb J, Zaanan A. Bergen ES, et al. Among authors: toullec c. Gastric Cancer. 2023 May;26(3):425-437. doi: 10.1007/s10120-023-01374-5. Epub 2023 Mar 7. Gastric Cancer. 2023. PMID: 36881202
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors.
Tran BT, Gelin A, Durand S, Texier M, Daste A, Toullec C, Benihoud K, Breuskin I, Gorphe P, Garic F, Brenner C, Le Tourneau C, Fayette J, Niki T, David M, Busson P, Even C. Tran BT, et al. Among authors: toullec c. Oncoimmunology. 2022 Dec 17;12(1):2150472. doi: 10.1080/2162402X.2022.2150472. eCollection 2023. Oncoimmunology. 2022. PMID: 36545254 Free PMC article.
Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching.
Adhoute X, De Matharel M, Mineur L, Pénaranda G, Ouizeman D, Toullec C, Tran A, Castellani P, Rollet A, Oules V, Perrier H, Si Ahmed SN, Bourliere M, Anty R. Adhoute X, et al. Among authors: toullec c. World J Gastrointest Oncol. 2022 Aug 15;14(8):1510-1527. doi: 10.4251/wjgo.v14.i8.1510. World J Gastrointest Oncol. 2022. PMID: 36160737 Free PMC article.
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T, Daste A, Saada-Bouzid E, Loundou A, Peyraud F, Lambert T, Le Tourneau C, Peyrade F, Dupuis C, Alfonsi M, Fayette J, Reure J, Huguet F, Fakhry N, Toullec C, Salas S. Chevalier T, et al. Among authors: toullec c. Cancer Med. 2021 Jun;10(12):3952-3963. doi: 10.1002/cam4.3953. Epub 2021 May 25. Cancer Med. 2021. PMID: 34080776 Free PMC article.
15 results